2025年指导
销售额：56亿 - 60亿美元（按不变汇率计算增长8% - 10%）
TAVR：41亿 - 44亿美元（按不变汇率计算增长5% - 7%）
TMTT：5亿 - 5.3亿美元（按不变汇率计算增长50% - 60%）
外科手术：9.7亿 - 10.5亿美元（按不变汇率计算增长中等个位数增长）
外汇对销售的影响：约1亿美元的不利影响（报告增长率下降约2点）
调整后毛利润率：78% - 79%
调整后运营利润率：27% - 28%
税率：15% - 18%
调整后每股收益：2.40 - 2.50美元
摊薄股份总数：5.85 - 5.95亿
预计2026年及以后的结构性心脏治疗法贡献增加；目标是公司销售额年均增长10%和每股收益两位数增长
主要来源于EARLY TAVR和PROGRESS驱动的TAVR中高个位数增长
TMTT对增长的贡献增加，预计到2030年达到20亿美元
包括结构性心力衰竭和AR在内的新治疗领域的贡献增加
以上内容来自Benzinga Earnings专栏，原文如下：
2025 Guidance
| Sales | $5.6 - $6.0 billion (8% - 10% constant currency growth) |
| TAVR | $4.1 - $4.4 billion (5% - 7% constant currency growth) |
| TMTT | $500 - $530 million (50% - 60% constant currency growth) |
| Surgical | $970 million - $1.05 billion (mid-single digit constant currency growth) |
| FX Impact on Sales | ~$100 million unfavorable (~2pt downside to reported growth) |
| Adjusted Gross Profit Margin | 78% - 79% |
| Adjusted Operating Margin | 27% - 28% |
| Tax Rate | 15% - 18% |
| Adjusted EPS | $2.40 - $2.50 |
| Diluted Shares Outstanding | 585 – 595 million |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.